Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.36 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.36 |
| ▸ | HIPK3 | Q9H422 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049877 | 0.90 | GRM4 (0.48) | GRM4KCNH2AKT1AKT2ILK | |
| SCHEMBL3706155 | 0.81 | GRM4 (0.42) | GRM4KCNH2AKT1AKT2ILK | |
| SCHEMBL1051979 | 0.81 | KCNH2 (0.42) | GRM4KCNH2AKT1AKT2ILK | |
| SCHEMBL1052763 | 0.75 | KCNH2 (0.43) | GRM4KCNH2AKT1AKT2ILK | |
| SCHEMBL1000214 | 0.74 | GRM4 (0.45) | GRM4KCNH2AKT1AKT2ILK | |
| SCHEMBL3703056 | 0.73 | GRM4 (0.39) | GRM4KCNH2CYP19A1 | |
| SCHEMBL31060271 | 0.73 | GRM4 (1.00) | GRM4KCNH2KDM4EMAPK1NPC1 | |
| SCHEMBL366994 | 0.73 | GRM4 (1.00) | GRM4KCNH2KDM4EMAPK1NPC1 | |
| SCHEMBL1051493 | 0.72 | GRM4 (0.42) | GRM4KCNH2AKT1AKT2ILK | |
| SCHEMBL1555341 | 0.71 | AKT2 (0.61) | GRM4KCNH2AKT1AKT2ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513252-B2 | Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-08-20 | — | — | US | claimed |
| EP-2456769-B1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-06-26 | — | — | EP | claimed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | claimed |
| US-8513252-B2 | Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2456769-B1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2456769-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2011010222-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM1, GRM4, GRM3 | GRM4 2/4885KCNH2 1226/4885AKT1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.